RECURRENT MEDULLOBLASTOMA

This study tests a drug called ivosidenib in children and young adults (ages 1-21) whose cancers have a specific IDH1 gene change and have either returned or not responded to standard treatments. The goal is to see if the drug can shrink tumors. Only 3 participants were enrolled,…

This study tests a drug called larotrectinib in children and young adults (ages 1 to 21) whose advanced or recurrent solid tumors, lymphoma, or histiocytic disorders have a specific genetic change called an NTRK fusion. The drug works by blocking enzymes that help cancer cells gr…

This study tests a drug called tipifarnib in children and young adults (ages 1 to 21) whose cancer has returned or spread and has a specific change in the HRAS gene. The goal is to see if the drug can shrink tumors or stop them from growing. About 5 participants received the drug…

This study tests a new treatment for children whose medulloblastoma or ependymoma has come back. It combines a specially designed antibody that delivers radiation directly into the brain fluid with standard chemotherapy drugs. The goal is to see if this approach can help children…

This study tests a drug called selpercatinib in children and young adults (ages 1 to 21) whose cancers have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. The trial is for patients with advanced solid…

This study tested the drug ensartinib in children and young adults (ages 1 to 21) whose advanced solid tumors, lymphoma, or related cancers had come back or stopped responding to treatment and had specific gene changes (ALK or ROS1). The goal was to see if the drug could shrink o…

This study aimed to test the safety of giving a combination of drugs (nivolumab plus either methotrexate or 5-azacytidine) directly into the fluid-filled spaces of the brain for people with recurrent brain tumors like medulloblastoma and ependymoma. The goal was to see if this di…

This study tests the drug ulixertinib in about 20 children and teens whose advanced solid tumors, lymphoma, or related blood disorders have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or stop the cancer. Participants must have already …

This early-stage trial is testing the safety and early effectiveness of a drug called pembrolizumab in children and young adults whose aggressive brain tumors have come back or stopped responding to standard treatments. The drug is a type of immunotherapy designed to help the bod…

This study screens children and young adults (ages 1-21) with advanced solid tumors, lymphomas, or related disorders that have not responded to standard therapy. Researchers analyze the genetic makeup of each patient's tumor to find specific mutations that can be targeted by cert…